A's trade Blanton

Thursday, July 17, 2008

The A's are trading Joe Blanton to Philadelphia for three minor-leaguers. Blanton, 27, is 5-12 with a 4.96 ERA this season, after going 14-10 with a 3.95 ERA last year.

"It's one of those deals where it's very bittersweet," Blanton told The Chronicle. "I'm going to a very good team with a very good lineup. They're in the division hunt and they're out to win a championship, and that's what any player wants. But I've always been with the A's, and I have great relationships there. It's one of those double-sided coins."

Blanton has had a rocky season. In a notable recent loss, on June 29 against the Giants in Oakland, he was tagged for seven runs and eight hits over four-plus innings in the Giants' 11-1 victory. In losing that game, he became the first pitcher in the AL to lose 11 games. At the time, he had given up 16 runs in his last 14 innings and lost five of six starts. He has been better at home (4.63 ERA) than away (5.74).

Blanton is 2-2 over his past four starts and in that stretch, he has been excellent in the first three innings, not allowing a run and giving up all of three hits in 39 at-bats (.077). From the fourth inning on in those four starts, he has an 11.25 ERA and the opponents are hitting .429.

The new A's are second baseman Adrian Cardenas, pitcher Josh Outman and outfielder Matthew Spencer.

Olney: Phils Trade Cardenas, Outman, and Spencer for Joe Blanton

Appearing on ESPN 950, Buster Olney has reported that the Phillies have traded a package of SS/2B Adrian Cardenas, P Josh Outman, and OF Matt Spencer to the A's for pitcher Joe Blanton.

Despite not being anywhere near a top-tier starter, Blanton brings a healthy appetite for innings to the Phillies rotation, though it will likely be as a 4th or even 5th man. His split stats show that he hurls better away from Oakland, but Citizens Bank Park isn't exactly pitcher-friendly, so we'll have to wait and see how those stats are affected by the new surroundings.

Olney says that although he won't always shine, Blanton should fit in well in Philly. He is hard-nosed and competitive, and he'll get through 6 on most nights, allowing the bullpen to stay fresh down the stretch. He'll also be in town through 2010, as opposed to the rentals that were snagged of off the market earlier (who were admittedly much bigger talents). The good news on Blanton is we already know his downside, as he's currently pitching as poorly as ever, but there's definitely a chance he could turn things around and become a solid starter here. He's only 27 after all. He's not the #2 this team desperately needed, but depth at SP is good no matter how you slice it. Right? Guys?

We'd like to know who the odd man out in the rotation is, since Brett Myers is set to return from his 'Piggin stint. Will the Phillies grant his wish and convert him to a reliever (albeit in a set-up role), or will they figure out a solution to the Adam Eaton situation?

Phils Inquiring About Joey Bland

We all know that starting pitching is the Phillies most pressing need, and also that they lost out on the premier talent that was available in CC and Rich Harden. The quality of the arms falls off a cliff after that point, and the Phils have been linked through scout-spotting to the Blue Jays for a few weeks now. The target in a Jays deal would be AJ Burnett, who can go from lights-out K master to Adam Eaton in just under 1.2 starts. On top of his inconsistency, he also has a very club-unfriendly contract situation. Unless the price is damn near free (and so far it's not), we'd probably be happy to see the Phils pass on Burnett.

Buster Olney [Insider] reports that those talks have indeed calmed down, but he confirms some rumors we've heard that the Phillies are now asking the A's about Joe Blanton.

After CC and Harden went to the NL Central, Pat Gillick made it clear the team would be looking at "B-list" pitchers, and Blanton is definitely in that category, if not lower. However, I didn't think much of Kyle Lohse before the Phils acquired him last year, and that turned out pretty well for the most part ('til he wasn't retained). But from what we've seen of Blanton, not only does he have Burnett's inconsistent start patterns, he's not all that great even when he's on. The Fightins crew is split on who they like more between Blanton and Burnett, which probably has more to do with concerns about which SP is worse rather than which is potentially better.

Blanton is currently sporting an ERA just south of 5.00, a 1.42 WHIP, and only 62 Ks in 122 innings. He's given up 6 or more runs in three of his last five starts (four times all season), so his trade value probably couldn't be much lower. With his ERA a full run higher than his final stats from 2007, maybe Gillick sees him as a buy-low candidate, but usually that banner is reserved for solid guys in a slump, not average guys who are pitching worse than usual. Also, Blanton's current ERA is almost exactly the same as he put up in 2006, so I think what we see is what we get. Somehow, he's put together 47 wins in 122 career starts, compared to 46 losses. On the Phillies rotation, he'd be no better than a fourth starter, which won't help much in the playoffs.

Still, if Billy Beane is just looking to dump at the deadline (he traded their best starter already, making them sellers in the market), Gillick owes the situation a look. I do get a little nervous thinking about Old Baseball Gillick and Moneyball Beane at the table though.

Blanton Traded to Phillies for 3 Prospects

According to Buster Olney at ESPN, the A's have sent Joe Blanton to Philadelphia for second baseman Adrian Cardenas, pitcher Josh Outman and outfielder Matthew Spencer.

The A's must really think Mark Ellis is going to leave as a free agent, as the A's are loading up on second base prospects all of a sudden. First they drafted Jemile Weeks, then they traded for Eric Patterson in the Rich Harden trade, and now they add Cardenas. Meanwhile, we're still stuck with no heir apparents to either Bobby Crosby or Eric Chavez.

But heck, you can't get a better name for a pitching prospect than Josh Outman, can you?

I like this trade better than the Harden trade, because I expected to get less from Blanton. But Cardenas and Outman are legit prospects. In the preseason, Kevin Goldstein gave them both 3-star ratings, while John Sickels ranked them both as solid B's. Spencer didn't make Goldstein's list, while Sickels gave him a C+.

BTW, if you don't like either of the two trades, you can blame this article of mine. I was literally two minutes from publishing it when the Rich Harden trade went down, and this Blanton trade goes through two minutes after I finally pressed the publish button on the thing.

Old Drug Dimebon Shows Promise in Alzheimer’s

A nearly forgotten allergy drug first used in Russia more than two decades ago is showing promise for the treatment of Alzheimer's disease.

In a study of the antihistamine Dimebon, Alzheimer's patients with mild to moderate disease continued to show improvements in memory, thinking, and daily and overall functioning over six months of treatment.

Some patients showed improvements when treated for up to a year.

Results from the Russian study were presented this week at the 60th annual meeting of the American Academy of Neurology (AAN) in Chicago. Study results were also reported last summer at an international conference on Alzheimer's disease.

Dimebon Alzheimer's Trial

Dimebon was approved as an antihistamine in Russia in the early 1980s.
It attracted attention as a potential Alzheimer's treatment following positive animal studies in 2000.

The human trial conducted in Russia included 183 patients with mild-to-moderate disease treated for six months with either Dimebon or placebo. Some patients continued to take the antihistamine for as long as a year.

Researchers reported significant improvement in memory, thinking, and other cognitive measures over placebo in as little as 12 weeks, and the differences were maintained over six months to a year.

Tests to measure mental function and interviews with caregivers confirmed improvements or disease stabilization in 81% of the Dimebon-treated patients after six months.

In a presentation delivered Thursday at the AAN meeting, Steven H. Ferris, PhD, reported that the drug's impact in Alzheimer's patients appears to be broad, rather than selective.

Ferris directs the Alzheimer's Disease Center at NYU School of Medicine.

"Our sub-analysis of the trial results suggests a broad, general benefit affecting language, memory, and other domains of cognition," Ferris tells WebMD.

International Trial Planned

The biopharmaceutical company Medivation Inc., which hopes to market Dimebon for the treatment of Alzheimer's in the U.S., is funding a second study of the drug to be conducted in the U.S., Europe, and South America.

If the earlier findings are confirmed, Medivation Inc. CEO David Hung, MD, tells WebMD that the company plans to petition the FDA for the drug's approval as an Alzheimer's treatment in 2010.

Dimebon has not been compared to the currently approved Alzheimer's drugs, but Hung says there are suggestions from the Russian study that it has a different mechanism of action that is unrelated to its antihistamine properties.

Three of the drugs -- Aricept, Razadyne, and Exelon -- block the activity of an enzyme in the brain called cholinesterase and are approved for the treatment of mild to moderate disease.

"What happens in Alzheimer's disease is that the neurons in the area of the brain that govern memory and thinking get sick and die," Hung says. "The cholinesterase inhibitors can slow this down, but they don't keep the cells from dying."

Early findings suggest that Dimebon may keep the neurons alive and even make sick neurons healthy again, he says.

Because many patients in the Russian trial showed improvements in memory and other aspects of mental functioning over time, there is some suggestion that the drug could modify the course of Alzheimer's disease.

Longer, rigorously designed studies would be needed to prove this, however.

Alzheimer's disease researcher Steven DeKosky, MD, who was not involved with the Dimebon research, calls the findings from the Russian study very promising. But he adds that the findings must be confirmed.

DeKosky directs the Alzheimer's Disease Research Center at the University of Pittsburgh.

"If the Russian findings hold up, that would be a big deal," he tells WebMD. "There isn't anything out there that works as well as this drug appeared to in that study. But there are still a lot of unanswered questions. We will know more when the phase III international trial is completed."

Medivation's Dimebon(TM) Significantly Improved Thinking And Memory In Alzheimer's Disease Patients Over One Year

Dimebon Significantly Improved Cognitive Function at One Year

The data presented at the AAN Annual Meeting included results of an analysis of the 11 subdomains of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), a standardized measure of cognition in patients with AD and one of two endpoints the U.S. Food and Drug Administration (FDA) has used to approve all currently marketed drugs for mild-to-moderate AD. In the study, ADAS-cog was assessed at the beginning of the study and at weeks 12, 26, 39 and 52.

Results showed that Dimebon-treated patients were significantly improved compared with placebo on 9 of the 11 ADAS-cog subdomains after one year of treatment. Benefits were observed in memory (word recall, p=0.04; word recognition, p=0.03; remembering instructions, p=0.10); orientation (p= 0.01); constructional praxis (the ability to copy simple drawings or patterns, p=0.005) and ideational praxis (the ability to perform a familiar but complex sequence of actions, p=0.006); and language (following commands, p<0.0001; naming objects, p<0.0001; word finding, p=0.005; comprehension, p=0.15; overall language, p=0.0002).

"We have recently presented a number of different findings from our first pivotal trial of Dimebon at scientific conferences, demonstrating that this investigational drug has a beneficial impact on the key aspects of Alzheimer's disease -- from behavioral symptoms to thinking and memory problems to impairments in daily function," said Lynn Seely, M.D., chief medical officer of Medivation. "Medivation is committed to rapidly developing Dimebon as a treatment for mild-to-moderate Alzheimer's disease to make it available to the millions of people who suffer from this increasingly prevalent disease, for which new treatment options are desperately needed."

Dimebon Showed Statistically Significant Benefit Versus Placebo on All Key Efficacy Endpoints

Medivation previously announced efficacy and safety results from the pivotal, 12-month, double-blind, placebo-controlled trial of Dimebon in 183 patients with mild-to-moderate AD. Dimebon improved the clinical course of Alzheimer's disease patients by causing statistically significant improvements over placebo in each of the five primary aspects of the disease -- memory, thinking, activities of daily living, behavior and overall clinical function. Significant gains over placebo were evident after as little as 12 weeks of treatment, and were maintained after both six months and a full year of treatment. In addition, after six months of treatment, Dimebon patients were significantly better on all five disease aspects than they were at the beginning of the study. The real-world impact of these data was evaluated by independent assessment, including caregiver interviews, which confirmed improvement or stabilization in 81 percent of Dimebon-treated patients after six months of treatment. Importantly, Dimebon's overall benefit compared to placebo continued to increase over time, and was larger at one year than at six months.

Dimebon was well-tolerated throughout the entire one-year treatment period. The majority of adverse events were mild, with dry mouth (18.0 percent Dimebon, 1.1 percent placebo) and depressed mood the most common events. There were significantly fewer serious adverse events in the Dimebon group than in the placebo group at one year.

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate AD in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

Dimebon

Overview

Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer’s disease and Huntington’s disease, making it a potential treatment for these and other neurodegenerative diseases. Based on clinical and preclinical data generated to date, Medivation believes that Dimebon works through a novel mechanism of action improving mitochondria function.

We are currently evaluating Dimebon in clinical trials for both Alzheimer’s disease and Huntington’s diseases.

Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease

SAN FRANCISCO, July 17, 2008 /PRNewswire-FirstCall via COMTEX/ -- Medivation, Inc. today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking, activities of daily living, behavior and overall function.

After both six months and a full year of treatment, Dimebon-treated patients were significantly better than placebo-treated patients on all key aspects of the disease. The benefit on the primary endpoint, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at six months, was highly significant (p<0.0001). Patients treated with Dimebon were also significantly improved at six months over baseline on all measures (p=0.005 on ADAS-cog). Dimebon's benefit over placebo continued to increase throughout the 12-month treatment period. At the end of 12 months, Dimebon-treated patients preserved their starting level of function on each measure of Alzheimer's disease.

"In this study, Dimebon improved the clinical course of Alzheimer's disease, which is important given that the natural course is progressive deterioration over time," said Rachelle Doody, M.D., Ph.D., lead author and the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. "There is a clear need for new treatments that can add value and enduring benefit to the treatment of Alzheimer's disease. The results of this trial suggest that, if the findings are replicated, Dimebon could advance Alzheimer's treatment, offering more hope for patients and their caregivers."

Dimebon was well-tolerated throughout the trial. There was no difference between the Dimebon and placebo groups in the number of patients with adverse events, and the most common side effects seen were dry mouth (18 percent versus 1 percent for placebo) and depressed mood/depression (15 percent versus 5 percent for placebo). Importantly, fewer patients treated with Dimebon had serious adverse events than did patients on placebo at the end of the study (3 percent versus 12 percent; p=0.03).

Additional analyses of the Dimebon pivotal study data presented at recent medical conferences showed that Dimebon's impact extended to caregivers. Behavioral improvements in Dimebon-treated patients resulted in a significant decrease in caregiver distress at six months and at one year compared to the distress of caregivers of placebo-treated patients. Further, after six months, caregivers of Dimebon-treated patients saved approximately one hour per day assisting patients with activities of daily living compared to caregivers of placebo-treated patients.

"The magnitude, consistency and duration of the beneficial effects of Dimebon demonstrated in this trial are striking," said Paul Aisen, M.D., Director, Alzheimer's Disease Cooperative Study (ADCS) and Professor in the Department of Neurosciences, University of California, San Diego (UCSD). "In addition, the drug has been well-tolerated to date and, if the safety profile is replicated in the ongoing international trial, it will be a substantial advance for this patient population prone to drug side effects."

"We are pleased to see our first pivotal trial culminate with publication of its significant findings in such a prestigious journal," said David Hung, M.D., President and Chief Executive Officer of Medivation. "Currently available therapies treat the symptoms of Alzheimer's disease with only modest effect. The Dimebon study is the first study in which a drug has achieved statistically significant benefits of this breadth, size and duration in a one year, well-controlled trial. These data, coupled with our recently announced positive results in Huntington's disease, suggest that Dimebon could be a novel therapy for the treatment of neurodegenerative diseases. We look forward to the completion of our confirmatory pivotal Phase 3 study of Dimebon in Alzheimer's disease."

About the Pivotal Study

In the trial, 183 patients with mild-to-moderate Alzheimer's disease were randomized to receive Dimebon (20 mg three times a day, administered orally) or placebo for six months. 134 patients continued treatment in a blinded manner for an additional six months (one year total treatment) in the same group to which they were originally randomized; 120 of these patients (90 percent) completed the trial.

Earlier this year, the U.S. Food and Drug Administration (FDA) informed Medivation that this study can be used as one of the pivotal studies required to support the approval of Dimebon to treat mild-to-moderate Alzheimer's disease, as long as a significant proportion of the sites in the confirmatory Phase 3 trial are located in the United States. The Company recently began a confirmatory pivotal Phase 3 trial of Dimebon in Alzheimer's disease known as the CONNECTION study. Patients and caregivers can learn more about the study by visiting http://www.connectionstudy.com or by calling 1-877-888-6386.

About Dimebon

Dimebon is an orally available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases. Preclinical data generated to date suggest that Dimebon operates through a novel mitochondrial mechanism of action.
On July 7, 2008, Medivation announced positive safety and efficacy results from its Phase 2 trial of Dimebon for the treatment of Huntington's disease, which was conducted in collaboration with the Huntington Study Group. The study met its primary endpoint of safety and tolerability; in addition, Dimebon showed statistically significant benefit versus placebo in cognition as measured by the Mini-Mental State Examination, a secondary endpoint in the study. Huntington's disease is a progressive neurodegenerative disease characterized by the gradual development of involuntary muscle movement, progressive deterioration of cognitive processes and memory and severe behavioral disturbances. There are currently no approved drugs in the United States to treat this uniformly fatal genetic disorder.

About Alzheimer's Disease

Alzheimer's disease is a progressive, neurodegenerative disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior, eventually leading to severe impairments in cognition and function. The most common form of dementia, Alzheimer's disease affects as many as 5 million Americans.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


SOURCE Medivation, Inc.

Angelina's secret sadness - by her brother

Even by the standards of Hollywood it is an extraordinary project.

When three-year-old Pham Quang Sang explores his new home for the first time this week, he will become the latest addition to what must be one of the fastest-growing families on the planet, not to mention the most colourful.

Little Pham, from Vietnam, joins Maddox from Cambodia, Zahara from Ethiopia and Shiloh, born in Namibia last May. Equally remarkable are the parents, Angelina Jolie and Brad Pitt, a superstar couple prepared to embrace domesticity on a heroic scale.

Ms Jolie has promised to adopt babies from every corner of the globe, without limit, and this is no empty threat. Already she has collected a family that resembles the United Nations.


angelina jolie

Family: Angelina Jolie, dad Jon Voight, and brother James Haven Voight

More showbiz news...
Coleen snacks in the sun ahead of 21st birthday bash
Naomi sparkles as her community service stint comes to a glittering end

She faces constant criticism, claims that she is a publicity-seeker, and demands that she take American babies instead of looking to the developing world for children.

But the 'Brangelina' circus rumbles on, unperturbed, which on past form is no surprise. Since she first hit stardom, she has been defiantly unconventional, whether it is boasting about unusual sex, showing off her collection of knives, or her large, and some will feel disfiguring, collection of tattoos.

Although recognised the world over, she is a woman truly known by very few, but her brother, 33-year-old actor and director James Haven Voight, can honestly claim to be one of them.

A reticent man who has spent much of his life in the shadow of his famous younger sister, he rarely seeks the limelight.

But with concern mounting about Angelina's behaviour, he has used his first-ever newspaper interview to defend her reputation and shed some light on the damaged and dysfunctional upbringing which has shaped them both.

In a fascinating insight into a very private world, he blames the bullying and manipulation of their handsome movie-hero father, Jon Voight, star of Midnight Cowboy, for blighting both their lives.

And he says it is the trauma of their childhood which has driven his sister to create a huge and independent family of her own.

Already emotionally vulnerable, the death of their mother in January of this year has left 31-year-old Angelina shattered. She is eating little and already seems to be losing her famous curves.

Now, more than ever, says her brother, she is determined to place her faith in the lives of the children - and who knows how many more there will be - she is gathering around her.

"I have no memory at all of my mother shouting at me or at my sister," James explains. "But I do have horrible memories of my father and the way he behaved. He was so tough on our mother.

"He lived in the same town. We saw him around Christmas time or at school recitals. He was always around but he never did his job as a father.

"I think one of the reasons Angelina and I care so much for other people is his treatment of our mother. Angelina and I were very protective of her for that reason."

It was their mother, Marcheline Bertrand, who provided the emotional underpinning to their lives, he says - the one point of stability amid the chaos. Her loss to cancer, aged just 56, has been devastating.

"Angie has become very thin because she's grieving," he admits. "It's even difficult for her to eat. I keep saying to her, 'Don't forget to eat'.

"But you know she doesn't pay much attention to food anyway and she's been going through a process of grief like me. She has not wanted to eat, nor has she been able to."

It ought to have been a privileged childhood for James and Angelina. Born in 1973 and 1975 respectively, they were members of Hollywood aristocracy. As teenagers they were educated at the Beverly Hills High School, alma mater to the stars - a school made more famous still by its central role in the long-running series Beverly Hills 90210.

Certainly, James remembers the domestic security of his mother's routine with affection.

"There was very much that home feeling when we came back from school," he recalls.

"Angie and I would walk in and comment on how we could smell things cooking and baking in the kitchen.

"My mum was methodical in making sure we did our homework perfectly. She would do outlines to help us. When we were younger, she used flash cards.

"Or she'd be in the middle of cooking and pick up a carrot and teach us about the vegetable or the fruit so that it was visual as well. Angie is now the same with her kids."

Marcheline, a beauty of mixed French-Canadian and Iroquois heritage, was an actress in her own right when she married Voight in 1971. But it was a brief partnership. They separated in 1976, shortly after Angelina's birth.

James and Angelina refuse to talk about the reasons for their parents' break-up - although there have been persistent rumours of womanising.

For all Marcheline's efforts to create a happy home, it was impossible to escape the destructive influence of Voight.

Money was one of many battlegrounds, although there should hardly have been a shortage of cash.

By 1975, he was a household name, handsome, blue-eyed and in demand.

Yet according to James, it was a constant battle - to the point that Angelina and her older brother were reduced to pleading with him to pay the child support he owed.

"I tried hard when I was alone with him," recalls James. "The alimony was always an issue. He would claim he was taking good care of her.

"But in reality Mum was stressing out and we had to tell him he was causing the problem. This would be when I was 13 and Angie was 11.

"We definitely had a taste of his manipulative behaviour. But it was when he dealt with my mother that we really saw him pulling the strings.

"And that made us very sad and angry. Angelina and I saw my mum oppressed. Now we're protective of women on their own and, of course, of children."

It was an experience which drove brother and sister closer and even today their relationship borders on intensity. H for 'Haven' is tattooed on Jolie's wrist.

Notoriously, she gave him a long and passionate kiss when celebrating her Oscar success for Girl, Interrupted in 2000.

James, who has the same striking looks as his sister, travels with Brad and Angelina on many of their foreign expeditions, and spends hours in the company of her growing brood.

Growing up, they never went hungry, but there were hardships. No one in Hollywood walks - Los Angeles is not built for the convenience of pedestrians - yet neither Angelina nor James could afford a car.

He explains: "One of the saddest things in my life happened when I was 16, which is when you can get your permit to drive in LA. I did not have a car in High School and neither did Angelina.

"Try to imagine. You go to Beverly Hills High, one of the wealthiest High Schools in the nation. Even the cheapest car that anyone has is brand new. All my friends are well off. I have a movie-star father and no car.

"It was debilitating. I did not to go to the prom [the social highlight of an American high school career] because I felt uncomfortable that Dad would have to drive me. It's an embarrassing thing.

"The significant years of dating and getting to know yourself, I didn't experience any of that. I didn't experience what I think is one of the most important times in a person's life, and neither did Angelina. It affected both of us.

"When I was in college and finally dating I went to my dad and told him what it was like for me in High School. He didn't try to understand at all. He said he didn't have money."

It was a lesson that neither of them forgot. James says: "Angie has been driven to be an independently wealthy woman now because we saw what it was like to be at the mercy of someone who controls the money and pulls the strings.

"There were times when our dad was awesomely good with us, but my biggest and most abiding memory is that he would look more to our faults than to our strengths."

It must, then, have been particularly hard to follow him in the movie industry. Certainly for all his sensitivity and good looks, James has scored only modest success with parts in the 2001 movies Original Sin - starring his sister - and Monster's Ball, which starred his sister's then husband, Billy Bob Thornton.

James says: "Look at what Angelina is doing - her work with the United Nations, raising awareness of refugees. It would just be great if Dad would commend her, or send her a message of encouragement. But she's never heard those words from him."

However, it did nothing to blunt her ambitions or her determination. In fact, the young Angelina was precocious in many ways.

This was a girl sufficiently confident to start a sexual relationship at the age of 14 and bring her lover back to live under the same roof with the tolerance, if not the approval, of her mother.

James denies that his sister is a domineering character, claiming that her famed decisiveness is, like her love of knives and her boasts about sadomasochistic sex, an attempt to be independent of other people's control.

But he is not ashamed to admit he is under her influence, in all sorts of ways.

"She's always been very protective of me with regards to my romantic life, which I love," he smiles. "She wants me to be with the right woman. When you come from a divorced home, divorce is what you desperately want to avoid.

"Maybe I haven't found the right woman because my sister is too picky for me. Any woman has to go through two filters, me and then my sister.

"I'm a perfectionist by nature. Then, because I'm so close to Angie it's like I've already got the perfect woman in my life and it's hard for anyone else to live up to that.

"I go to Angie for advice and won't do anything without her because we were so close as children."

Her influence on him is so profound, he claims he has even been persuaded to adopt a child himself - provided he can find a partner first. Angelina has even brought about a change of career, persuading him to spend large parts of his time campaigning for charity. He is currently preparing to take part in a major US campaign to fight the AIDS pandemic in Uganda.

James is outraged by the claim that their relationship might in any way be inappropriate - claims prompted by 'that' kiss after the 2000 Oscars.

"I did not give Angie a French kiss, it was something simple and lovely," he insists.

"She was about to go off to Mexico to finish filming Original Sin with Antonio Banderas. I congratulated her on the Oscar win and gave her a quick kiss on the lips. It was snapped and became a big thing round the world."

It seemed at one point the fractured relationship between Angelina and her father was on the mend. The pair took part in the 2001 movie Lara Croft: Tomb Raider, for example, with Voight playing her on-screen father.

But Voight spoiled it by going on Access Hollywood, a prime-time US talk show, and accusing his daughter of having 'serious mental problems'. Jolie responded by legally erasing her surname, Voight, and banning him from seeing her children. They have not spoken since.

Voight's relationship with his son, meanwhile, is a little better. But not much. Voight has yet to talk to James in person following the death of his mother, an omission the son finds barely able to believe.

"My dad left a voicemail message that was very kind, wishing condolences to me and my sister. That was what he did," says James, his voice heavy with sarcasm.

Now, with the death of their mother, the wound is red raw.

"He was very tough on my mum for years and then the person he was tough on has gone. He can't do anything now, he can't fix that and it's very painful," James says.

"At some point I've got to be able to let my bitterness and anger towards him go and I'm working on that now. I believe my mother's in a better place. What I have to deal with is that there's no such thing as him making amends now - he's lost his chance and that just makes me and Angelina even more upset.

"When I first lost my mother, I couldn't stop crying. Fortunately, I was with Angie when we heard. It was such a big moment.

"If Angelina understood something about missing parents before, she understands completely now. Angelina and I are orphans too, in a way. When you see those kids in orphanages, they cling to each other. And that's exactly what they have - they have each other."

James Haven Visits Sister Angelina Jolie & The Twins

NICE, France -Angelina Jolie’s brother, James Haven, stopped by to visit his sister and her newborns earlier today in France.

Haven was captured by an Associated Press photographer entering Nice’s Hospital Lenval, at around 10 AM local time.

In a baseball cap, sunglasses and red gym top, Haven arrived at the hospital surrounded by bodyguards, according to People.

Haven pulled up in a Mercedes with blacked out windows.

Angelina and her newborns – Knox Leon and Vivienne Marcheline — are still at the hospital, where she gave birth to the babies via C-section over the weekend.

Haven was last spotted at the facility when he brought Angelina’s first child, Maddox, to see his mom, on July 5, People reported.

Anuar Ibrahim Caught Again


Supposed that today I'm already not really in mood due to some lady's sick.When I reach home after work,i thought of having a nice bath and then have a great nap/rest.But out of sudden,my mum asked me for some minor help-fetch the maid back to agent's office and pick up my bro from school.

So,after my bath,I drop down 'kakak' first then drive all the way to town to fetch my bro.When I'm back,one of my course mate asked me about my result.I was totally blank and got very nervous with that.I tried many way to get myself logged in but after few hours trying with that,my username blocked.I dare not to wait,so..i dare up myself to complain for the complicated web info.Is kinda confusing when I go through the web site.Few minutes later,the in charge person reset my password to the origin password.And finally,i can log in already.At the very first glance,I was happy with my result..BUT when I scroll down further......

OMG..I can't believe I got such 'ugly' result.

I've broken my own heart and my very own hope.I thought that I can prove it to my parents,but seems like I need to work triple harder compared to previous sem!I even thought that some one could accompany m and talk to me to pass this night.

Second big disappoint drop on me again.On a very first that i heard when I answer a call,I heard the unexpected background-car engine running on.Because I really thought that he can forgo his outing for 1 night and to talk to me..but.......

Thirdly,I even think that I can handle my disappointment but seems like,I can't make myself to have a better sleep tonight.

Too many surprise with a big disappointment happen at the same time,on the same day and what bad is..it happen before I sleep.Tomorrow,I still need to stand from 11am to 5pm.I'm here wondering,under hot sun/temperature,without sleeping at night,and headache,will i faint down again like last time I always does during school time..??

At this late night,I can't do anything..Most peoples sleep.So,what I can do now is listen to MY FM and also HITZ FM while blogging.And now,I found that I really make full use of my laptop.Ah,I downloaded all those latest news from BULETIN UTAMA,TV3 which something related to Dato' Anuar Ibrahim and also our economy.

PKR de facto leader Anwar Ibrahim, was arrested yesterday at 1PM after finished giving a statement to the Anti-Corruption Agency in Putrajaya regarding in his 'black-eye' incident in 1998.

When there will be a break for this thing ! Malaysian concentrating in growing it but there's interruption in building the community well !

Emmy Nominees Announced Today!


This morning, we brought you the Emmy noms live online as Neil Patrick Harris ("How I Met Your Mother") and Kristen Chenoweth ("Pushing Daisies") announced this year's contenders!

America Ferrera made the list again for Outstanding Lead Actress In A Comedy Series with her performance on "Ugly Betty," which earned her the trophy last year. She is joined by fellow funny ladies Mary-Louise Parker, ("Weeds") Tina Fey, ("30 Rock") Christina Applegate ("Samantha Who?") and Julia Louis-Dreyfus ("The New Adventures of Old Christine").

Their male counterparts include the hilarious Tony Shalhoub ("Monk"), Steve Carell ("The Office"), Lee Pace ("Pushing Daisies"), Alec Baldwin ("30 Rock") and Charlie Sheen ("Two And A Half Men").

Charlie tells ET: "I'm extremely proud of our show. I'm flattered and honored to be nominated, and as usual, I am more excited for my fellow 'Two and a Half Men' nominees."

Out of the top 10 comedies previously announced for consideration, "Curb Your Enthusiasm," "Entourage," "The Office," "30 Rock" and "Two And A Half Men" made the cut.

In the drama category, "Boston Legal," "Damages," "Dexter," "House," "Lost" and "Mad Men" took the top slots.

Taking top nods with 23 bids is HBO's historical drama "John Adams." Paul Giamatti, who played Adams, is up for best lead actor.

"30 Rock" followed with 17 noms, "Mad Men" with 16, "Pushing Daisies" with 12, "Recount" with 11, "Bernard and Doris" with 10, "Tin Man" with 9, the mini-series "Cranford", "Dancing with the Stars" and "The Office" with 8 noms each.

For the first time ever, the awards will include a trophy for Outstanding Host For A Reality Or Reality-Competition Program. Ryan Seacrest, Tom Bergeron, Howie Mandel, Heidi Klum and Jeff Probst have the honor of being the first nominated in this new category.

In a surprise move, both Neil and Kristen were told they're nominated in the Outstanding Supporting Actor/Actress categories! They're joined by Jeremy Piven ("Entourage"), Kevin Dillon ("Entourage"), Rainn Wilson ("The Office"), Jon Cryer ("Two And A Half Men"), Jean Smart ("Samantha Who?"), Amy Poehler ("Saturday Night Live"), Holland Taylor ("Two And A Half Men") and Vanessa Williams ("Ugly Betty").

Upon learning of her nomination, Vanessa told us that she is "happy to be nominated amongst such an amazing group of women. I'm a huge fan of all of their work."

Privacy Policy